艾美疫苗无血清狂犬疫苗获受理通知书

财中社
08 Apr

  4月7日,艾美疫苗(06660)发布公告,宣布其研发的无血清迭代狂犬疫苗获得国家药品监督管理局的《受理通知书》,受理号为CXSS2500044。同时,公司全资子公司艾美荣誉(宁波)生物制药有限公司已取得该疫苗的生产许可证。这一进展标志着公司在狂犬疫苗领域实现了重大技术突破,预计将进一步巩固其全球领先地位。

  目前,全球市场上尚无无血清狂犬疫苗获得批准上市,该产品的上市有望填补市场空白。根据灼识咨询的统计,中国的狂犬疫苗市场预计到2030年将达到148亿元。公司表示,凭借其迭代技术优势,无血清迭代狂犬疫苗有望成为疫苗接种机构的首选,未来的上市销售将大幅提升公司的业绩。

(文章来源:财中社)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10